Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia
Magdalena L. Bochenek, … , Wolfram Ruf, Katrin Schäfer
Magdalena L. Bochenek, … , Wolfram Ruf, Katrin Schäfer
Published June 14, 2022
Citation Information: JCI Insight. 2022;7(14):e157701. https://doi.org/10.1172/jci.insight.157701.
View: Text | PDF
Research Article Angiogenesis Vascular biology

EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia

  • Text
  • PDF
Abstract

Blood clot formation initiates ischemic events, but coagulation roles during postischemic tissue repair are poorly understood. The endothelial protein C receptor (EPCR) regulates coagulation, as well as immune and vascular signaling, by protease activated receptors (PARs). Here, we show that endothelial EPCR-PAR1 signaling supports reperfusion and neovascularization in hindlimb ischemia in mice. Whereas deletion of PAR2 or PAR4 did not impair angiogenesis, EPCR and PAR1 deficiency or PAR1 resistance to cleavage by activated protein C caused markedly reduced postischemic reperfusion in vivo and angiogenesis in vitro. These findings were corroborated by biased PAR1 agonism in isolated primary endothelial cells. Loss of EPCR-PAR1 signaling upregulated hemoglobin expression and reduced endothelial nitric oxide (NO) bioavailability. Defective angiogenic sprouting was rescued by the NO donor DETA-NO, whereas NO scavenging increased hemoglobin and mesenchymal marker expression in human and mouse endothelial cells. Vascular specimens from patients with ischemic peripheral artery disease exhibited increased hemoglobin expression, and soluble EPCR and NO levels were reduced in plasma. Our data implicate endothelial EPCR-PAR1 signaling in the hypoxic response of endothelial cells and identify suppression of hemoglobin expression as an unexpected link between coagulation signaling, preservation of endothelial cell NO bioavailability, support of neovascularization, and prevention of fibrosis.

Authors

Magdalena L. Bochenek, Rajinikanth Gogiraju, Stefanie Großmann, Janina Krug, Jennifer Orth, Sabine Reyda, George S. Georgiadis, Henri M. Spronk, Stavros Konstantinides, Thomas Münzel, John H. Griffin, Philipp Wild, Christine Espinola-Klein, Wolfram Ruf, Katrin Schäfer

×

Figure 6

Endothelial EPCR and hemoglobin expression and soluble EPCR plasma levels in patients with chronic peripheral artery ischemia.

Options: View larger image (or click on image) Download as PowerPoint
Endothelial EPCR and hemoglobin expression and soluble EPCR plasma level...
(A) Representative IHC images of human skeletal muscle specimens from nonischemic controls (top panel) and patients with peripheral artery disease (PAD) showing expression of EPCR, HBA, and eNOS+ endothelial cells; n = 4 biological replicates. Scale bars: 10 μm. (B) Representative IHC images of human PAD specimens showing expression of HBA, CD31, and EPCR on serial cross sections. Scale bars: 10 μm (upper row). Lower row shows enlarged areas of interest. Images are taken with 200× (upper row) and 400× (lower row) magnification. (C) Results of quantitative analysis of the number of positive cells residing in vascular specimens isolated from patients with PAD; n = 4 biological replicates. **P < 0.01; 1-way ANOVA, Bonferroni’s multiple-comparison test. (D) Plasma levels of soluble EPCR (sEPCR) in 19 patients with PAD and 19 age- and sex-matched individuals with similar risk factors (RF) and no PAD diagnosis (controls with RF). (E) Plasma levels of nitrite/nitrate in patients with PAD and age-and sex-matched controls. *P < 0.05 and **P < 0.01. Student’s t test.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts